San Diego-based biopharmaceutical company Gossamer Bio (NASDAQ: GOSS) announced it will host a live webcast for investors and analysts on Monday, December 18th to discuss the latest clinical data from an ongoing late-stage trial evaluating its inhaled drug seralutinib for the treatment of pulmonary arterial hypertension (PAH).
PAH is a progressive and life-threatening lung disorder characterized by increased blood pressure in the arteries supplying the lungs, which can lead to heart failure. There are limited treatment options available for this rare disease that impacts 30,000 to 50,000 individuals in the US.
Seralutinib is an oral tyrosine kinase inhibitor that targets signaling pathways involved in the pathogenesis of PAH. It has been specifically formulated using a dry powder inhaler to enable direct delivery to lungs. Gossamer believes this approach can provide clinical benefits over current standard of care drugs while also improving patient compliance and quality of life.
The webcast will feature the latest efficacy and safety data from the ongoing open-label extension (OLE) portion of the Phase 2 TORREY study evaluating seralutinib in PAH patients. Earlier results from this mid-stage trial showed seralutinib significantly improved exercise capacity and cardiac output while demonstrating a favorable safety and tolerability profile after 24 weeks of treatment.
Gossamer’s CEO Sheila Gujrathi, M.D., noted, “We are excited to share these new seralutinib clinical data with the investment community, which we believe continue to support its potential to become a uniquely differentiated inhaled treatment option for PAH patients in need of new therapies.”
The investor event will be held on December 18th at 8:30 AM Eastern Time. A live audio webcast will be accessible through Gossamer’s website, or participants can directly dial-in by phone. A replay of the webcast will also be made available on the company’s site afterwards.
Gossamer is aiming to complete regulatory submissions next year to support initiation of a global Phase 3 program for inhaled seralutinib in PAH during the second half of 2024. If successful, it believes seralutinib could represent a best-in-class therapy and significant commercial opportunity given the drug’s novel targeted mechanism of action and patient-friendly inhaled delivery.
